View in EDS

Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.

Saved in:
Bibliographic Details
Title: Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.
Authors: Surana R; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Morgado M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Somasundaram A; Division of Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Bockorny B; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA., Weekes CD; Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA., Coleman EC; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Bird A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Wang J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Williams HL; Department of Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Zheng H; Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA., Brais LK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Saxena N; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Graham C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Ritterband L; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Sawin M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Peters ML; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA., Whooley P; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA., Bullock A; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA., Zerillo J; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA., Sanoff HK; Division of Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Clark JW; Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA., Parikh AR; Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA., Yurgelun MB; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Patel AK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Mayer RJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Enzinger P; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Rubinson DA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., McCleary NJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Enzinger A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Slater S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Biller LH; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Abrams TA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Huffman BM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Singh H; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Raghavan S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Mancias JD; Department of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Bryant KL; Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Nowak JO; Department of Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Der CJ; Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Perez K; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Source: JCO precision oncology [JCO Precis Oncol] 2025 Sep; Vol. 9, pp. e2500332. Date of Electronic Publication: 2025 Sep 02.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40893054
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Surana+R%22">Surana R</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Morgado+M%22">Morgado M</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Somasundaram+A%22">Somasundaram A</searchLink>; Division of Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Bockorny+B%22">Bockorny B</searchLink>; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Weekes+CD%22">Weekes CD</searchLink>; Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Coleman+EC%22">Coleman EC</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Bird+A%22">Bird A</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Williams+HL%22">Williams HL</searchLink>; Department of Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Zheng+H%22">Zheng H</searchLink>; Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Brais+LK%22">Brais LK</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Saxena+N%22">Saxena N</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Graham+C%22">Graham C</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Ritterband+L%22">Ritterband L</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Sawin+M%22">Sawin M</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Peters+ML%22">Peters ML</searchLink>; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Whooley+P%22">Whooley P</searchLink>; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Bullock+A%22">Bullock A</searchLink>; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Zerillo+J%22">Zerillo J</searchLink>; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Sanoff+HK%22">Sanoff HK</searchLink>; Division of Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Clark+JW%22">Clark JW</searchLink>; Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Parikh+AR%22">Parikh AR</searchLink>; Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Yurgelun+MB%22">Yurgelun MB</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Patel+AK%22">Patel AK</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Mayer+RJ%22">Mayer RJ</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Cleary+JM%22">Cleary JM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Enzinger+P%22">Enzinger P</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Rubinson+DA%22">Rubinson DA</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22McCleary+NJ%22">McCleary NJ</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Enzinger+A%22">Enzinger A</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Slater+S%22">Slater S</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Ng+K%22">Ng K</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Biller+LH%22">Biller LH</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Abrams+TA%22">Abrams TA</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Huffman+BM%22">Huffman BM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Singh+H%22">Singh H</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Raghavan+S%22">Raghavan S</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Mancias+JD%22">Mancias JD</searchLink>; Department of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Bryant+KL%22">Bryant KL</searchLink>; Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Nowak+JO%22">Nowak JO</searchLink>; Department of Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Aguirre+AJ%22">Aguirre AJ</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Der+CJ%22">Der CJ</searchLink>; Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Wolpin+BM%22">Wolpin BM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Perez+K%22">Perez K</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101705370%22">JCO precision oncology</searchLink> [JCO Precis Oncol] 2025 Sep; Vol. 9, pp. e2500332. <i>Date of Electronic Publication: </i>2025 Sep 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101705370 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-4284 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224734284%22">24734284 </searchLink><i>NLM ISO Abbreviation: </i>JCO Precis Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40893054
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/PO-25-00332
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e2500332
    Titles:
      – TitleFull: Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Surana R
      – PersonEntity:
          Name:
            NameFull: Morgado M
      – PersonEntity:
          Name:
            NameFull: Somasundaram A
      – PersonEntity:
          Name:
            NameFull: Bockorny B
      – PersonEntity:
          Name:
            NameFull: Weekes CD
      – PersonEntity:
          Name:
            NameFull: Coleman EC
      – PersonEntity:
          Name:
            NameFull: Bird A
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: Williams HL
      – PersonEntity:
          Name:
            NameFull: Zheng H
      – PersonEntity:
          Name:
            NameFull: Brais LK
      – PersonEntity:
          Name:
            NameFull: Saxena N
      – PersonEntity:
          Name:
            NameFull: Graham C
      – PersonEntity:
          Name:
            NameFull: Ritterband L
      – PersonEntity:
          Name:
            NameFull: Sawin M
      – PersonEntity:
          Name:
            NameFull: Peters ML
      – PersonEntity:
          Name:
            NameFull: Whooley P
      – PersonEntity:
          Name:
            NameFull: Bullock A
      – PersonEntity:
          Name:
            NameFull: Zerillo J
      – PersonEntity:
          Name:
            NameFull: Sanoff HK
      – PersonEntity:
          Name:
            NameFull: Clark JW
      – PersonEntity:
          Name:
            NameFull: Parikh AR
      – PersonEntity:
          Name:
            NameFull: Yurgelun MB
      – PersonEntity:
          Name:
            NameFull: Patel AK
      – PersonEntity:
          Name:
            NameFull: Mayer RJ
      – PersonEntity:
          Name:
            NameFull: Cleary JM
      – PersonEntity:
          Name:
            NameFull: Enzinger P
      – PersonEntity:
          Name:
            NameFull: Rubinson DA
      – PersonEntity:
          Name:
            NameFull: McCleary NJ
      – PersonEntity:
          Name:
            NameFull: Enzinger A
      – PersonEntity:
          Name:
            NameFull: Slater S
      – PersonEntity:
          Name:
            NameFull: Ng K
      – PersonEntity:
          Name:
            NameFull: Biller LH
      – PersonEntity:
          Name:
            NameFull: Abrams TA
      – PersonEntity:
          Name:
            NameFull: Huffman BM
      – PersonEntity:
          Name:
            NameFull: Singh H
      – PersonEntity:
          Name:
            NameFull: Raghavan S
      – PersonEntity:
          Name:
            NameFull: Mancias JD
      – PersonEntity:
          Name:
            NameFull: Bryant KL
      – PersonEntity:
          Name:
            NameFull: Nowak JO
      – PersonEntity:
          Name:
            NameFull: Aguirre AJ
      – PersonEntity:
          Name:
            NameFull: Der CJ
      – PersonEntity:
          Name:
            NameFull: Wolpin BM
      – PersonEntity:
          Name:
            NameFull: Perez K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2025 Sep
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2473-4284
          Numbering:
            – Type: volume
              Value: 9
          Titles:
            – TitleFull: JCO precision oncology
              Type: main
ResultId 1